Medical Dialogues
  • Dermatology
Sign in Signup
This site is intended for healthcare professionals only
Sign in Signup
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
Medical Dialogues
  • Medical News
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Medical Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
  • MDTV
      • Anesthesia
      • CTVS
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • Diet and nutrition
      • ENT
      • Gastroenterology
      • Health Dialogues
      • Health News today
      • Health Shorts
      • Health Updates
      • Health video of the day
      • Laboratory Medicine
      • Latest Videos
      • Latest Webinars
      • MD shorts
      • Medical News Today
      • Medical Updates
      • Medical Video of the day
      • Medicine
      • Nephrology
      • Neurology and Neurosurgery
      • Obstetrics and Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics & Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Top Videos
      • Urology
This site is intended for healthcare professionals only
Sign InRegister
Medical Dialogues
Sign inRegister
  • Home
  • Medical news
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Medical Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
  • Case of the Day
  • Editorial
  • Home
  • Pediatrics and Neonatology
  • Pediatrics and Neonatology News
  • No benefit of...

No benefit of nebulized magnesium with albuterol in reractory pediatric asthma: JAMA

Dr. Kamal Kant KohliBy Dr. Kamal Kant KohliPublished On 2020-11-26T16:15:15+05:30  |  Updated On 2020-11-26T14:15:26+05:30
No benefit of nebulized magnesium with albuterol in reractory pediatric asthma: JAMA

A recent study in children with refractory acute asthma showed nebulized magnesium with albuterol, compared with placebo with albuterol, did not significantly decrease the hospitalization rate for asthma within 24 hours.The trial details have been published in the JAMA Network on November 24, 2020. Previously published pediatric asthma studies of nebulized magnesium were small, and...

A recent study in children with refractory acute asthma showed nebulized magnesium with albuterol, compared with placebo with albuterol, did not significantly decrease the hospitalization rate for asthma within 24 hours.

The trial details have been published in the JAMA Network on November 24, 2020.

Previously published pediatric asthma studies of nebulized magnesium were small, and had methodological limitations such as lack of focus on health care utilization outcomes and not limiting participants to those not responsive to initial optimized care. But, the Magnesium Nebulization Utilization Management in Pediatric Asthma (MAGNUM PA) Trial was designed to evaluate the effectiveness of inhaled magnesium in children who presented in the Emergency Department with an acute asthma exacerbation and remained in moderate or severe respiratory distress after evidence-based standardized initial therapy.

Researchers designed a randomized, double-blind, parallel-group, placebo-controlled trial comparing the effect of nebulized magnesium sulfate with albuterol vs placebo with albuterol. The trial duration was between September 26, 2011, and November 19, 2019, in 7 tertiary-care pediatric emergency departments in Canada. Among 5846 screened children, 4332 were excluded, 273 declined participation, 423 otherwise excluded, 818 were randomized, and 816 children with refractory acute asthma were analyzed.

The participants were randomly assigned to nebulized albuterol treatments with either magnesium sulfate (n = 410) or 5.5% saline placebo (n = 408) received 3 consecutive nebulization treatments, consisting of 5 mg (1 mL) of albuterol and either 600 mg (1.2 mL) of magnesium sulfate (Sandoz) or 1.2 mL of 5.5% saline. Sterile water (3.8 mL) was added to each nebulization treatment in both groups to achieve identical tonicity of both intervention and placebo solutions. Researchers set the primary outcome as physicians' decision to hospitalize children for persistent respiratory distress or the need for supplemental oxygen within 24 hours of randomization. Pediatric Respiratory Assessment Measure (PRAM) score; respiratory rate; oxygen saturation at 60, 120, 180, and 240 minutes; changes in blood pressure at 20, 40, 60, 120, 180, and 240 minutes; and albuterol treatments within 240 minutes were considered as secondary outcomes. Adverse drug reactions were monitored and codified using MedDRA.

KEY FINDINGS OF THE STUDY WERE:

The hospitalization rate in magnesium group was 43.5% and for placebo group it was 47.7% suggesting no statistically significant treatment effect of magnesium and albuterol vs placebo

There were no significant differences between the groups in the changes from baseline to 240 minutes in PRAM score (difference in changes are 0.14 points)

The difference in change for respiratory rate was 0.31 breaths/min; For oxygen saturation, it was −0.05% and for systolic blood pressure, it was 0.61 mm Hg suggesting no significant difference between the 2 groups.

The Mean number of additional albuterol treatments for the magnesium group was 1.49 and for the placebo group it was 1.59

Nausea/vomiting or sore throat/nose occurred in 17 of the 409 children who received magnesium (4%) and 5 of the 407 who received placebo (1%).

The authors concluded, "Among children with refractory acute asthma in the ED, nebulized magnesium with albuterol, compared with placebo with albuterol, did not significantly decrease the hospitalization rate for asthma within 24 hours."

"The findings do not support the use of nebulized magnesium with albuterol among children with refractory acute asthma" the authors further added.

For further information  log on to:

JAMA. 2020;324(20):2038-2047. doi:10.1001/jama.2020.19839

Nebulized Magnesium Albuterol asthma pediatric asthma MAGNUM PA Trial Journal of American Medical Association 
Source : JAMA Network
Dr. Kamal Kant Kohli
Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as an Editor-in-Chief for the Speciality Medical Dialogues section. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Before Joining Medical Dialogues, he has served at important positions in the medical industry in India including as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils in India. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Treatment challenges in managing Gastroparesis related to PPI Use: Analyzing scope of Probiotics

    Treatment challenges in managing Gastroparesis related to PPI Use: Analyzing scope of Probiotics

    Review: Efficacy of Antiviral Agents Against  Omicron Subvariant BA.2

    Review: Efficacy of Antiviral Agents Against Omicron Subvariant BA.2

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Choice of Antibiotics in Common Infections: Doxycycline or Azithromycin?

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    Role of acyclovir in Management of chickenpox: Analyzing the importance of starting early

    Parkinsonism and the place of Amantadine - Review Analysis

    Parkinsonism and the place of Amantadine - Review Analysis

    View All

    Journal Club Today

    Twincretin Tirzepatide Recieves FDA Approval for Type 2 Diabetes

    'Twincretin' Tirzepatide Recieves FDA Approval for Type 2 Diabetes

    View All

    Health News Today

    Health Bulletin 17/May/2022

    Health Bulletin 17/May/2022

    View All
    © 2019 All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X